Abstracts

Filters

Clear Filters
All Days Sun, Sep 27 Mon, Sep 28 Tue, Sep 29 Wed, Sep 30

Monday, September 28

3:15 PM - 3:20 PM ET

1074 - A Phase II Randomized Blinded Trial of AI-Assisted Versus Manual Contouring by New Learners in Ultrasound-Based Prostate HDR Brachytherapy
Speaker: Thomsen, Bryce, MD - Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston, MA
3:20 PM - 3:25 PM ET

1045 - Pembrolizumab and Stereotactic Radiosurgery (SRS) of Selected Brain Metastases in Breast Cancer Patients
Speaker: Gregucci, Fabiana - Weill Cornell Medical College, New York, NY
3:20 PM - 3:25 PM ET

1051 - The ART of SABR: A Randomized Phase II Trial of Near "Margin-less" Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer: Two vs. Five Fractions
Speaker: Waddle, Mark, MD - Mayo Clinic College of Medicine Jacksonville, Jacksonville, FL
3:20 PM - 3:25 PM ET

1057 - Stereotactic Body Radiotherapy Combined with Chemotherapy and PD-1 Inhibitor in Oligometastatic Nasopharyngeal Carcinoma (STOMP): A Prospective Phase II Clinical Trial
Speaker: Miao, Jingjing, PhD, MS, BS - Sun Yat-sen University Cancer Center, Guangzhou, Guangdong
3:20 PM - 3:25 PM ET

1063 - From Feasibility to Clinical Practice: Direct-to-Treatment Ultra-Hypofractionated Whole-Breast ART with AI-Based Segmentation
Speaker: Parsons, David, PhD - University of Texas Southwestern Medical Center, Dallas, TX
3:20 PM - 3:25 PM ET

1075 - Auto-Segmented Organ-at-Risk Volume Variability as a Patient-Specific Predictive Biomarker for Gastrointestinal Toxicity Risk Stratification in Abdominal Radiotherapy
Speaker: Lasington, Jeril, MD - NYMC-Saint Clare's Health and Saint Mary's general hospital, Denville, NJ
3:20 PM - 3:30 PM ET

212 - Long-Term Outcomes of Definitive Chemoradiotherapy Plus Toripalimab for Locally Advanced Cervical Cancer: A Single-Center Phase II Trial with Integrated Pretreatment Transcriptomic Correlatives
Speaker: Cao, Yuan Jie, MD, PhD - Tianjin Medical University Cancer Institute and Hospital, Tian Jin, Tian Jin
3:20 PM - 3:30 PM ET

217 - Pelvic Radiation-Induced Tumors in Mice Recapitulate the Histologic and Anatomic Spectrum of Human Secondary Malignancies
Speaker: Kincaid, John, MS, MPhil - Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Boston, MA
3:20 PM - 3:30 PM ET

223 - Standardizing Major Joint Contours: Dosimetric Analysis among Soft Tissue Sarcoma Patients
Speaker: Harris, Jeremy, MD, MPhil - University of California, Irvine, Orange, CA
3:25 PM - 3:30 PM ET

1046 - Hematologic Toxicity, Treatment Completion Time, and Dosimetric Comparison between Proton and Photon Craniospinal Irradiation in Pediatric Tumor Patients: A Propensity Score-Matched Study
Speaker: Li, Ran, PhD - Shandong Cancer Hospital, Shandong Provincial Key Medical and Health Laboratory of Pediatric Cancer Precision Radiotherapy, Ji Nan
3:25 PM - 3:30 PM ET

1052 - Results of a Phase 2 Trial of Prostate SBRT with Integrated Tumor Boost and Dose Reduction at Urethra, Bladder and Rectal Interfaces
Speaker: Wilson, Trevor, MD - University of Wisconsin, Madison, WI
3:25 PM - 3:30 PM ET

1058 - Similar Overall Survival in Oropharyngeal Cancer Patients Treated with IMRT vs. Proton Therapy
Speaker: Wu, Yingzhi, MSN - Memorial Sloan Kettering Cancer Center, New York, NY